UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $63.70 Million Holdings in LifeStance Health Group, Inc. $LFST

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) by 2.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,947,600 shares of the company’s stock after selling 144,623 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 1.53% of LifeStance Health Group worth $63,699,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of LifeStance Health Group during the second quarter worth approximately $389,293,000. Silversmith Partners I GP LLC acquired a new position in LifeStance Health Group in the 4th quarter valued at approximately $100,842,000. Vanguard Group Inc. increased its stake in LifeStance Health Group by 21.1% in the 4th quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock valued at $124,608,000 after buying an additional 3,086,506 shares during the period. Wellington Management Group LLP purchased a new stake in LifeStance Health Group in the 2nd quarter worth approximately $30,881,000. Finally, Jennison Associates LLC lifted its position in LifeStance Health Group by 38.5% in the 1st quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock worth $65,157,000 after buying an additional 2,843,388 shares in the last quarter. Institutional investors and hedge funds own 85.50% of the company’s stock.

Insider Buying and Selling

In other LifeStance Health Group news, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $10.62, for a total value of $144,890,858.34. Following the completion of the sale, the insider owned 98,101,407 shares of the company’s stock, valued at $1,041,836,942.34. The trade was a 12.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Lisa K. Miller sold 47,912 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $10.85, for a total value of $519,845.20. Following the sale, the chief operating officer owned 281,289 shares of the company’s stock, valued at approximately $3,051,985.65. This trade represents a 14.55% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 14,629,850 shares of company stock valued at $154,952,012 in the last three months. 3.50% of the stock is currently owned by corporate insiders.

LifeStance Health Group Stock Performance

Shares of LFST opened at $12.89 on Thursday. The company’s fifty day moving average is $11.38 and its 200-day moving average is $8.73. LifeStance Health Group, Inc. has a 12 month low of $4.77 and a 12 month high of $13.15. The firm has a market cap of $5.00 billion, a price-to-earnings ratio of 99.16 and a beta of 1.22. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03. The business had revenue of $435.35 million during the quarter, compared to analyst estimates of $414.58 million. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. LifeStance Health Group’s quarterly revenue was up 26.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.01) EPS. Equities analysts expect that LifeStance Health Group, Inc. will post 0.16 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Wall Street Zen upgraded shares of LifeStance Health Group from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 15th. BTIG Research increased their price objective on LifeStance Health Group from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, August 19th. The Goldman Sachs Group initiated coverage on LifeStance Health Group in a research report on Friday, June 5th. They set a “neutral” rating and a $9.00 price objective for the company. Canaccord Genuity Group boosted their target price on LifeStance Health Group from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Finally, JPMorgan Chase & Co. boosted their target price on LifeStance Health Group from $9.00 to $13.00 and gave the company a “neutral” rating in a research note on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $12.38.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.